Immunovant, Inc. (IMVT)
Develops antibody drugs to treat autoimmune diseases like rheumatoid arthritis and Graves' disease.
$38.62-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+145.8%
The outlook
Analysts are strongly bullish on IMVT, with a consensus rating near "Strong Buy" and an average price target about 23% above the current level. The stock is trading well above its 50- and 200-day moving averages and sits near its 52-week high, showing upward momentum. StockGlow's overall assessment leans decidedly bullish based on current technical and sentiment data.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 15 analysts
Price trendAbove its 50- & 200-day averages
52-week range90% of the way from its 52-week low to high
Price targetAvg target +23% vs current price
Analyst price target
~12-month · 15 analysts$47.53average target+23.1% vs now
Now $38.62
Low $24.00High $66.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$7.93B
52-wk high
$41.23
52-wk low
$14.32
50-day avg
$35.64
200-day avg
$27.62
Trailing P/E
—